Although these considerations need additional validations in context of PDAC, they are supported from clinical data in multiple myeloma, where MYC seem to be connected to a benefit of proteasome inhibitor‐based therapy [68, 69]. This evidence concerns the gene MYC and plasma cell myeloma.